Kezar Life Sciences, Inc. (NASDAQ:KZR) Sees Large Growth in Short Interest

Kezar Life Sciences, Inc. (NASDAQ:KZR) was the target of a significant increase in short interest during the month of September. As of September 30th, there was short interest totalling 982,900 shares, an increase of 13.6% from the September 15th total of 865,600 shares. Based on an average daily trading volume, of 834,500 shares, the short-interest ratio is currently 1.2 days.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Fidelis Capital Partners LLC bought a new position in Kezar Life Sciences in the 1st quarter worth approximately $25,000. Mackenzie Financial Corp purchased a new position in shares of Kezar Life Sciences in the second quarter worth $35,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Kezar Life Sciences during the second quarter worth $63,000. Marquette Asset Management LLC purchased a new position in Kezar Life Sciences during the first quarter valued at $114,000. Finally, BNP Paribas Financial Markets increased its holdings in Kezar Life Sciences by 35.4% in the 1st quarter. BNP Paribas Financial Markets now owns 273,430 shares of the company’s stock valued at $247,000 after acquiring an additional 71,543 shares during the last quarter. Institutional investors own 67.90% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “neutral” rating on shares of Kezar Life Sciences in a research note on Monday.

Kezar Life Sciences Stock Performance

Shares of KZR opened at $0.87 on Wednesday. The business has a 50-day simple moving average of $0.64 and a two-hundred day simple moving average of $0.69. The company has a quick ratio of 9.58, a current ratio of 9.58 and a debt-to-equity ratio of 0.05. Kezar Life Sciences has a 52 week low of $0.52 and a 52 week high of $1.14. The stock has a market cap of $63.34 million, a price-to-earnings ratio of -0.62 and a beta of 0.21.

Kezar Life Sciences (NASDAQ:KZR) last released its earnings results on Tuesday, August 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.04. On average, analysts expect that Kezar Life Sciences will post -1.2 EPS for the current year.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.